Towa Pharmaceutical Co., Ltd. (FRA:6QC)
Germany · Delayed Price · Currency is EUR 23.40
+0.20 (0.86%)
At close: Feb 20, 2026
Towa Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 28,788 | 26,330 | 24,459 | 4,605 | 22,246 | 18,728 |
Depreciation & Amortization | 22,123 | 20,099 | 17,888 | 19,409 | 10,954 | 10,425 |
Loss (Gain) From Sale of Assets | -65 | -218 | -225 | 478 | -96 | -97 |
Loss (Gain) From Sale of Investments | 3 | 3 | -18 | 19 | 5 | -17 |
Other Operating Activities | 870 | -10,046 | -1,036 | -5,910 | -4,437 | -5,803 |
Change in Accounts Receivable | -1,385 | -565 | -15,523 | -1,592 | 441 | -4,544 |
Change in Inventory | -10,674 | -7,204 | -6,288 | -18,496 | -7,950 | -9,707 |
Change in Accounts Payable | 264 | 3,687 | -10,509 | 6,554 | 3,675 | 2,451 |
Change in Other Net Operating Assets | -9,095 | -8,685 | -536 | -2,523 | -2,709 | 572 |
Operating Cash Flow | 30,829 | 23,401 | 8,212 | 2,544 | 22,129 | 12,008 |
Operating Cash Flow Growth | 98.51% | 184.96% | 222.80% | -88.50% | 84.28% | -37.34% |
Capital Expenditures | -24,491 | -28,736 | -37,851 | -28,731 | -11,140 | -9,137 |
Sale of Property, Plant & Equipment | 9 | 9 | 1 | 239 | 42 | 3 |
Cash Acquisitions | - | - | -1,570 | - | -45,405 | -894 |
Sale (Purchase) of Intangibles | -1,728 | -2,211 | -1,055 | -1,723 | -2,353 | -501 |
Investment in Securities | -1,467 | -203 | -50 | -267 | 17 | - |
Other Investing Activities | -68 | -146 | 131 | 198 | -220 | 205 |
Investing Cash Flow | -27,745 | -31,287 | -40,394 | -30,284 | -59,729 | -9,100 |
Short-Term Debt Issued | - | 1,603 | - | - | 47,135 | - |
Long-Term Debt Issued | - | 26,365 | 46,935 | 78,831 | 9,160 | 40,500 |
Total Debt Issued | 14,086 | 27,968 | 46,935 | 78,831 | 56,295 | 40,500 |
Short-Term Debt Repaid | - | - | -768 | -45,680 | - | -20,251 |
Long-Term Debt Repaid | - | -12,592 | -7,607 | -12,268 | -7,181 | -17,745 |
Total Debt Repaid | -13,203 | -12,592 | -8,375 | -57,948 | -7,181 | -37,996 |
Net Debt Issued (Repaid) | 883 | 15,376 | 38,560 | 20,883 | 49,114 | 2,504 |
Issuance of Common Stock | - | - | - | - | 21 | - |
Common Dividends Paid | -3,912 | -2,953 | -2,952 | -3,100 | -2,411 | -2,166 |
Other Financing Activities | 9,117 | 9,144 | -201 | -302 | -184 | -154 |
Financing Cash Flow | 6,088 | 21,567 | 35,407 | 17,481 | 46,540 | 184 |
Foreign Exchange Rate Adjustments | 1,149 | 1,916 | 2,167 | 1,685 | 975 | 761 |
Miscellaneous Cash Flow Adjustments | -1 | 212 | 1 | 1 | - | 348 |
Net Cash Flow | 10,320 | 15,809 | 5,393 | -8,573 | 9,915 | 4,201 |
Free Cash Flow | 6,338 | -5,335 | -29,639 | -26,187 | 10,989 | 2,871 |
Free Cash Flow Growth | - | - | - | - | 282.76% | -80.36% |
Free Cash Flow Margin | 2.35% | -2.05% | -13.00% | -12.54% | 6.64% | 1.85% |
Free Cash Flow Per Share | 128.75 | -108.38 | -602.17 | -532.02 | 218.36 | 55.99 |
Cash Interest Paid | 2,109 | 1,594 | 941 | 610 | 226 | 172 |
Cash Income Tax Paid | 8,596 | 10,889 | 1,760 | 6,285 | 4,748 | 6,231 |
Levered Free Cash Flow | -7,418 | -15,700 | -32,622 | -27,055 | -1,466 | 2,521 |
Unlevered Free Cash Flow | -6,077 | -14,683 | -32,030 | -26,658 | -1,322 | 2,640 |
Change in Working Capital | -20,890 | -12,767 | -32,856 | -16,057 | -6,543 | -11,228 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.